Enanta Pharmaceuticals (ENTA) Competitors $11.30 +0.22 (+1.99%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$11.30 0.00 (0.00%) As of 10/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ENTA vs. TERN, ANAB, PVLA, MGTX, SIGA, OLMA, KROS, BCAX, KALV, and GOSSShould you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Enanta Pharmaceuticals vs. Its Competitors Terns Pharmaceuticals AnaptysBio Palvella Therapeutics MeiraGTx Siga Technologies Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics KalVista Pharmaceuticals Gossamer Bio Terns Pharmaceuticals (NASDAQ:TERN) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Does the media prefer TERN or ENTA? In the previous week, Enanta Pharmaceuticals had 2 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 8 mentions for Enanta Pharmaceuticals and 6 mentions for Terns Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.80 beat Terns Pharmaceuticals' score of -0.10 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Enanta Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TERN or ENTA more profitable? Terns Pharmaceuticals has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -141.98%. Terns Pharmaceuticals' return on equity of -27.35% beat Enanta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -27.35% -26.18% Enanta Pharmaceuticals -141.98%-89.02%-27.28% Which has higher earnings and valuation, TERN or ENTA? Terns Pharmaceuticals has higher earnings, but lower revenue than Enanta Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.04-7.94Enanta Pharmaceuticals$67.64M3.57-$116.04M-$4.32-2.62 Do analysts recommend TERN or ENTA? Terns Pharmaceuticals currently has a consensus target price of $15.49, indicating a potential upside of 87.51%. Enanta Pharmaceuticals has a consensus target price of $20.83, indicating a potential upside of 84.37%. Given Terns Pharmaceuticals' higher probable upside, research analysts plainly believe Terns Pharmaceuticals is more favorable than Enanta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Which has more risk and volatility, TERN or ENTA? Terns Pharmaceuticals has a beta of -0.03, suggesting that its stock price is 103% less volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do insiders & institutionals believe in TERN or ENTA? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by company insiders. Comparatively, 13.9% of Enanta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryEnanta Pharmaceuticals beats Terns Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Enanta Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTA vs. The Competition Export to ExcelMetricEnanta PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$236.87M$2.64B$6.10B$10.55BDividend YieldN/A56.71%5.69%4.75%P/E Ratio-2.6223.6985.4727.60Price / Sales3.57556.27582.22224.03Price / CashN/A173.2337.9261.55Price / Book1.865.5313.136.76Net Income-$116.04M$32.78M$3.30B$275.88M7 Day Performance9.39%5.82%4.29%2.81%1 Month Performance25.00%13.16%9.45%9.24%1 Year Performance5.51%1.69%86.64%35.42% Enanta Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTAEnanta Pharmaceuticals4.0611 of 5 stars$11.30+2.0%$20.83+84.4%+2.7%$236.87M$67.64M-2.62160Analyst ForecastTERNTerns Pharmaceuticals3.7152 of 5 stars$7.79+2.0%$15.49+98.8%+5.8%$668.58MN/A-7.4940Analyst ForecastANABAnaptysBio2.5084 of 5 stars$23.27-1.3%$46.13+98.2%-1.6%$660.17M$91.28M-5.19100Analyst ForecastGap UpPVLAPalvella Therapeutics2.0527 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AAnalyst ForecastMGTXMeiraGTx4.0582 of 5 stars$8.25+0.9%$24.00+190.9%+99.0%$658.06M$33.28M-4.04300News CoverageAnalyst ForecastInsider TradeSIGASiga Technologies1.8567 of 5 stars$8.96-2.2%N/A+24.1%$655.91M$138.72M7.9340Analyst ForecastOLMAOlema Pharmaceuticals2.6445 of 5 stars$9.54+0.3%$24.00+151.6%-5.9%$652.71MN/A-4.8270News CoverageAnalyst ForecastKROSKeros Therapeutics2.8317 of 5 stars$15.95-0.6%$30.00+88.1%-73.3%$651.88M$3.55M51.45100Analyst ForecastBCAXBicara Therapeutics2.3177 of 5 stars$13.87+18.4%$32.25+132.5%-20.2%$638.93MN/A-4.3832News CoverageInsider TradeHigh Trading VolumeKALVKalVista Pharmaceuticals3.8263 of 5 stars$12.21-1.5%$26.43+116.5%+2.5%$626.49MN/A-3.10100Analyst ForecastGOSSGossamer Bio3.9067 of 5 stars$2.82+4.4%$8.50+201.4%+137.3%$613.93M$114.70M-4.55180Analyst Forecast Related Companies and Tools Related Companies TERN Competitors ANAB Competitors PVLA Competitors MGTX Competitors SIGA Competitors OLMA Competitors KROS Competitors BCAX Competitors KALV Competitors GOSS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enanta Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
